Table 2. Sensitivity and specificity of methylation markers and cytology on physician-taken material for CIN2+ and CIN3+ (n=128).
| Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|---|---|
| Test | CIN2+ | CIN3+ | ||
| C13ORF18 | 49% (34.4–63.7) | 92% (84.2–97.1) | 65% (46.5–80.2) | 91% (83.9–96.2) |
| JAM3 | 63% (48.3–76.6) | 90% (81.0–95.5) | 82% (65.5–93.2) | 88% (80.0–94.0) |
| EPB41L3 | 67% (52.5–80.0) | 57% (45.3–68.1) | 88% (72.5–96.6) | 61% (50.0–70.6) |
| TERT | 69% (54.6–81.7) | 62% (50.4–72.7) | 76% (58.8–89.2) | 60% (49.0–69.6) |
| Abnormal cytology (⩾ASCUS) | 84% (70.3–92.7) | 51% (39.1–62.1) | 91% (76.3–98.0) | 48% (37.5–58.4) |
Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CI=confidence interval.